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treatment with the mGluR5 PAM, CDDPB (30 mg/kg), on glutamatergic receptor expression at adolescence
(PN35) and adulthood (PN96). Immunoblot analysis revealed that 7-day adolescent CDPPB treatment
increased protein expression of glutamatergic receptors including the NMDA receptor subunits, NR1 and
NR2A and the AMPA subunits (GluA1 and GluA2) in the adolescent hippocampus, changes that did not
extend to adulthood. In contrast, there were no changes in the adolescent frontal cortex, however elevated
mGluR5 protein expression was observed at adulthood following adolescent CDPPB treatment. The present
study indicates adolescent CDPPB treatment may cause brain region dependent effects on the glutamatergic
system, which do not persist into adulthood. These findings may have implications for the preclinical
development of mGluR5 PAMs for the treatment of neurodevelopmental disorders.
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Abstract (150-250 words) 
Dysfunction of the glutamatergic system is believed to underlie many neurodevelopmental disorders including 
autism, Rett syndrome and schizophrenia. Metabotropic glutamate receptor (mGluR5) positive allosteric 
modulators (PAM) potentiate glutamatergic signaling, particularly indirectly via the NMDA receptor. Preclinical 
studies report mGluR5 PAMs can improve schizophrenia-relevant behaviours. Furthermore, adolescent 
administration has shown to prevent cognitive induced deficits in adult rodents. However, there is limited 
understanding of the short- and long-term neurochemical effects of mGluR5 PAMs, which may underlie their 
therapeutic effects. We examined the effect of 7-day adolescent (PN28-34) treatment with the mGluR5 PAM, 
CDDPB (30 mg/kg), on glutamatergic receptor expression at adolescence (PN35) and adulthood (PN96). 
Immunoblot analysis revealed that 7-day adolescent CDPPB treatment increased protein expression of 
glutamatergic receptors including the NMDA receptor subunits, NR1 and NR2A and the AMPA subunits (GluA1 
and GluA2) in the adolescent hippocampus, changes that did not extend to adulthood. In contrast, there were no 
changes in the adolescent frontal cortex, however elevated mGluR5 protein expression was observed at adulthood 
following adolescent CDPPB treatment. The present study indicates adolescent CDPPB treatment may cause brain 
region dependent effects on the glutamatergic system, which do not persist into adulthood. These findings may 
have implications for the preclinical development of mGluR5 PAMs for the treatment of neurodevelopmental 
disorders.   
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Glutamate is the major excitatory neurotransmitter in the central nervous system, playing an important role in 
neurodevelopment and cognitive processes [1, 2]. Dysfunction of the glutamatergic system, particularly in the 
frontal cortex and hippocampus, has been identified in a number of cognitive and neurodevelopmental disorders 
such as schizophrenia, Rett syndrome and autism [3, 4]. Glutamate exerts its effects via two classes of receptors; 
ionotropic ligand-gated ion channels, including N-methyl-D-aspartate (NMDA), α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA) and kainate and metabotropic G-protein-coupled receptors (mGluR) 1-8. 
mGluRs are categorised into 3 groups based on their sequence homology, G-protein coupling and pharmacology; 
Group 1 (mGluR1 and 5), Group 2 (mGluR2-3) and Group 3 (mGluR4,6-8) which regulate the activity of 
ionotropic glutamate receptors. Therefore mGluRs have become highly attractive pharmacotherapeutic targets for 
modulating ionotropic receptors, in particular the NMDA receptor dysfunction, proposed to underlie cognitive 
deficits in a range of neurological disorders [5].  
Metabotropic glutamate receptor 5 (mGluR5) shares a physical and functional relationship with the NMDA 
receptor, via interactions with scaffolding proteins including Homer, SH3 and multiple ankyrin repeated domains 
(SHANK), guanylate-kinase-associated protein (GKAP) and post-synaptic density 95 (PSD-95) [6].  Knockout or 
pharmacological blockade of mGluR5 in rodents has shown to cause heightened cognitive impairment, induced 
via NMDA receptor antagonism [7–9]. Additionally, two endogenous regulators of mGluR5, Norbin and 
Homer1b/c, which increase mGluR5-stimulated release of Ca2+ from intracellular stores, cell surface localisation 
and downstream signalling, play a role in synaptic plasticity and cognition [10]; Norbin and Homer1 KO mice 
display deficits in working and spatial memory [11–13], accompanied by increased behavioural sensitivity to 
NMDA receptor antagonism. Furthermore, agonist-induced activation of mGluR5 potentiates NMDA and AMPA 
receptor mediated currents [14–17], a process crucial for synaptic plasticity. These findings support the notion, 
that mGluR5 activation may represent a novel target to increase glutamatergic signalling and improve cognition. 
However, long-term treatment with agonists can lead to receptor desensitisation and seizures. Positive allosteric 
modulators (PAMs) may overcome this issue, as they rely on endogenous cycling of the neurotransmitter, 
glutamate. Similar to mGluR5 agonists, mGluR5 PAMs enhance long-term potentiation and long-term depression 
[18, 19], processes closely reliant on NMDA and AMPA receptor expression and activity. Furthermore, rodent 
studies have reported mGluR5 PAMs, including ADX-47273, CDPPB (3-cyano-N-(1,3-diphenyl-1H-pyrazol-5-
yl)benzamide) and VU-analogues improve cognitive measures including spatial, working and/or declarative 
memory [18, 20–22]. 
Several studies investigating the therapeutic potential of mGluR5 PAMs have focused on administering these 
compounds at adult time points and have shown promising efficacy in the treatment of various behavioural deficits 
[6]. However, it is apparent that many of the proposed disorders where mGluR5 PAMs may be advantageous, are 
neurodevelopmental, where early intervention could be beneficial and possibly preventative. Kjaerby and 
colleagues reported sub-chronic administration with the mGluR5 PAM, ADX-47273, at adolescence (PN25-32) 
was able to attenuate neonatal phencyclidine induced sensorimotor gating deficits [23]. In a similar model, Clifton 
and colleagues demonstrated that early adolescent intervention with the mGluR5 PAM, CDPPB, attenuated 
neonatal phencyclidine-induced social cognition deficits at adulthood [24].  
4 
 
mGluR5 PAMs have shown promising behavioural potential, yet little is known about their influence on 
neurochemical transmission, which may underlie their behavioural efficacy. Acute CDPPB administration in adult 
rats increased synaptic expression and phosphorylation of the NMDA receptor (NR1 and NR2B subunits) and 
AMPA receptor (GluA1 subunit) in the frontal cortex and hippocampus, which was associated with improvements 
in recognition memory [22]. Similarly, Parmentier-Batteur and colleagues showed CDPPB treatment in adult rats 
caused brain region dependent effects on NMDA receptor expression and phosphorylation in the striatum and 
frontal cortex after 7-days of treatment [25]. Whether adolescent CDPPB treatment causes changes to 
neurochemistry, and whether these effects persist after treatment ends, is unknown. The present study aimed to 
investigate the effects of adolescent CDPPB treatment on glutamatergic transmission in the frontal cortex and 
hippocampus, regions involved in cognitive behaviour and dysfunction, and determine whether any effects are 
long lasting into adulthood. 
 
Methods 
Animals and Drug Treatment 
Pregnant Sprague-Dawley rats (gestational day 14) were obtained from the Animal Resources Centre (Perth, 
Australia). Dams were housed individually, under constant temperature control (20oC) and 12:12 hour light-dark 
cycle. Dams were provided food and water ad libitum. Following birth, pups were continually housed with their 
dam and littermates until postnatal day (PN) 21. At PN 21, male offspring were separated from their 
dams/littermates and housed in random pairs of the same treatment group, with ad libitum access to food and 
water. On PN 28, male rats received intraperitoneal (i.p) injections of CDPPB (30 mg/kg; 3 ml/kg) or vehicle 
(10:10:80 dimethyl sulfoxide, Tween 20, 0.9% NaCl) at a dose of 3 ul/g, once a day for 7 consecutive days from 
PN 28-34, considered to represent adolescence [26]. This dose of CDPPB (30 mg/kg) has previously shown to 
enhance performance in spatial learning tasks [27] and ameliorate NMDA receptor antagonist-induced cognitive 
set-shifting deficits [28]. One cohort of animals was euthanised by carbon dioxide asphyxiation at PN 35 (24 hrs 
after final injection) to examine the adolescent brains. The second cohort (adult) were continually pair housed and 
euthanised by carbon dioxide asphyxiation at PN 98 (adulthood; 9 weeks after final treatment). The brains were 
immediately removed and the frontal cortex and hippocampus were dissected according to a standard rat brain 
atlas [29], before being frozen in liquid nitrogen and stored at -80oC.  
Tissue preparation and Immunoblotting 
Tissue samples (left and right hemispheres combined) were homogenised in 5 x (w/v) the volume of 
homogenisation buffer containing 0.1 M Tris-HCl, 2 mM ethylenediaminetetraacetic acid, 10% glycerol, 1% 
sodium dodecyl sulfate (SDS), 100 mM iodoacetamide, 0.5 mM phenylmethylsulfonyl fluoride, Protease Inhibitor 
Cocktail (P8340; Sigma, Australia) and Phosphatase Inhibitor Cocktail 2 (Sigma, Australia). Total protein 
concentration was determined using a detergent compatible assay kit as per the manufacturer’s instructions (Bio-
Rad, Australia). Protein (5 ug) was diluted in laemmli buffer (not containing reducing agents e.g. β-
mercaptoethanol or dithiothreitol) and separated by SDS-polyacrylamide gel electrophoresis in 4-20% TGXTM 
precast gels (Bio-Rad, Australia). Proteins were transferred on polyvinylidene fluoride membranes and blocked 
with either 5% bovine serum albumin or skim milk (w/v) for 1 hr at room temperature. The membranes were 
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incubated in primary antibodies at the following concentrations: anti-mGluR5 (1:5000; ab29170, Abcam); NMDA 
receptor subunits: anti-NR1 (1:5000; MAB363, Millipore), anti-NR2A (1:5000; MAB5530, Millipore) and anti-
NR2B (1:5000; MAB5578, Millipore); AMPA receptor subunits: anti-GluA1 (1:10 000; ab31232, Abcam) and 
anti-GluA2 (1:10 000; ab133477, Abcam); anti-Neurochondrin (Norbin) (1:7500; ab130507, Abcam); anti-
Homer1b/c (1:7500; ab211415, Abcam); PSD-95 (1:10 000; MAB1598, Millipore); or GAPDH (1:50 000, 
OSG00032W, Osenses) at 4oC overnight. Subsequently, membranes were incubated with anti-rabbit or -mouse 
peroxidase-conjugated secondary antibodies (1:5000; Millipore). Bands were visualised using Amersham 
enhanced chemiluminescence western blotting detection reagent (GE Healthcare, Australia) and exposed to 
Hyperfilm (GE Healthcare, Australia). Films were scanned using a GS-800 scanner (Bio-Rad) and the expected 
bands for each respective antibody was quantified by densitometry using Quantity One (Bio-Rad). Relative 
densitometry values were normalised to their respective GAPDH values and an internal control value (consisting 
of equal amounts of each sample, pooled together), to account for protein loading and gel-gel variability, 
respectively. Each sample was run in duplicate or triplicate. 
Statistics 
Statistical analyses were performed using SPSS Software (Version 21). Shapiro-Wilk tests were performed to 
identify distribution of data. Multivariate analysis of variance (MANOVA) were employed to identify differences 
between CDPPB and vehicle treated groups of the same brain-region and age. Data sets that were not normally 
distributed, as determined by Shapiro-Wilk scores (p<0.05) or did not fit Levene’s test of equality were analysed 
by Mann-Whitney-U tests. The level of significance was set to p<0.05.  
 
Results 
To investigate the effects of chronic adolescent CDPPB treatment on the glutamatergic system, western blots were 
employed to measure the relative protein levels of NMDA receptor subunits (NR1, NR2A and NR2B), AMPA 
receptor subunits (GluA1 and GluA2), PSD-95, dimeric mGluR5 and two key endogenous regulators of mGluR5, 
Norbin and Homer1b/c. In the adolescent and adult hippocampus and frontal cortex, all proteins were clearly 
identified at their expected molecular weights, as previously reported [30].  
Chronic adolescent CDPPB treatment acutely increases hippocampal, but not frontal cortical, 
glutamatergic receptors 
Analysis of the adolescent hippocampus revealed mGluR5 protein expression was significantly up regulated 
following chronic adolescent CDPPB treatment (64%; F1,8=10.481, p=0.018; Fig 1). However, we observed no 
changes to the mGluR5 endogenous regulators, Norbin and Homer1b/c. Protein levels of the obligatory NR1 
subunit and NR2A subunit, but not the NR2B subunit, were also increased (NR1: 17%; F1,9=14.519, p=0.009; 
NR2A: 63%, F1,9=7.934, p=0.030; NR2B: F1,9=2.310, p=0.179). Adolescent CDPPB treatment further increased 
both GluA1 and GluA2 protein levels in the hippocampus (GluA1: 157%; F1,8= 13.597, p=0.01; GluA2: 21%, 
F1,10=7.097, p<0.037).  Although there was a trend for PSD-95 protein expression to be increased in the 
hippocampus following adolescent CDPPB treatment, this did not reach statistical significance (46%; F1,10=4.371, 
p=0.082). The measured glutamatergic proteins were not altered in the adolescent frontal cortex following chronic 
adolescent CDPPB treatment (Fig 2).  
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Chronic adolescent CDPPB treatment does not cause long-term changes to hippocampal glutamatergic 
receptors but increases mGluR5 in the frontal cortex  
Analysis of the adult hippocampus revealed GluA2 was significantly decreased following adolescent CDPPB 
treatment (-21%; F1,12=6.165, p=0.030), with no other changes in the proteins measured (Fig 3).  In the adult 
frontal cortex, mGluR5 protein expression was significantly upregulated following adolescent CDPPB treatment 
(71%; F1,12=30.927, p<0.001; Fig 4). Protein levels of the mGluR5 endogenous regulator, Norbin, were decreased 
in the frontal cortex although this did not reach statistical significance (-19%; p=0.054). We observed no changes 
to the other proteins measured in the adult frontal cortex, following CDPPB treatment.  
 
Discussion 
mGluR5 PAMs have been proposed as a therapeutic strategy for several neurodevelopmental and psychiatric 
disorders, including autism, Rett syndrome and schizophrenia. Adolescent intervention with mGluR5 PAMs has 
shown to attenuate schizophrenia-like behaviours in rodent models [23, 24], however, little is known about the 
short- and long-term neurochemical treatment effects during this time-point. We investigated the effects of 
adolescent CDPPB treatment on the glutamatergic system and determined whether these effects persist into 
adulthood. Our results indicate adolescent CDPPB treatment causes short-term up regulation of glutamatergic 
receptors in the hippocampus, but not the frontal cortex. These effects were not observed at adulthood, suggesting 
adolescent CDPPB treatment causes acute and brain region-specific effects. 
mGluR5 is a vital unit in the hub of post-synaptic glutamatergic signalling, linking to the NMDA receptor via 
several scaffolding proteins, including Homer1. Stimulation of mGluR5 with agonists or PAMs has been shown 
to increase the activation of NMDA receptors and increase hippocampal synaptic plasticity, which is thought to 
contribute to the cognitive enhancing potential of mGluR5 PAMs [18, 31]. In the present study, chronic adolescent 
CDPPB treatment caused an up regulation of mGluR5 protein expression in the adolescent hippocampus. 
However, CDPPB treatment did not alter the expression of Homer1b/c or Norbin, two endogenous regulators of 
mGluR5 thought underlie mGluR5’s role in cognition. Nevertheless, we observed acute increases in expression 
of NR1 and NR2A as well as the AMPA GluA1 and GluA2 subunits. These findings are consistent with reports 
from Uslaner et al., [22] where an acute dose of CDPPB (30mg/kg) in adult rats increased hippocampal NR1 and 
GluA1 expression and phosphorylation (Ser831). Additionally, these increases were associated with improved 
performance in novel object recognition tasks, suggesting increases in NMDA and AMPA expression/activity 
may underlie CDPPB’s cognitive enhancing properties.  
Whilst we observed changes in glutamatergic receptor expression in the hippocampus, we did not observe any 
changes to protein expression in the adolescent frontal cortex between CDPPB treated and control animals. 
Parmentier-Batteur and colleagues [25] observed increased NMDA receptor subunit phosphorylation and 
expression in the adult frontal cortex and striatum following acute CDPPB treatment (30mg/kg). However, 
following sub-chronic 7-day CDPPB treatment (30mg/kg, daily), these changes were no longer present in the 
frontal cortex, which they suggest may indicate this region is vulnerable to mGluR5 desensitisation. Similarly, we 
did not observe changes to glutamatergic receptor expression in the adolescent frontal cortex following 7-day 
CDPPB treatment, however changes were present in the hippocampus, supporting brain region-specific effects of 
CDPPB treatment. Further supporting these differential brain region effects, Uslaner et al. [22] showed that acute 
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CDPPB treatment, at the same dose used in the present study, caused increased NMDA receptor subunit 
expression and phosphorylation in the hippocampus, but not the frontal cortex. However, the authors illustrated 
the effects of CDPPB administration on protein expression in the frontal cortex were characterised by an inverted 
U-shaped dose-dependent response, whereby a lower dose of 10mg/kg CDPPB increased NMDA and AMPA 
receptor subunits and phosphorylation.  Collectively, the present results support previous findings that CDPPB 
may cause brain region specific and dose dependent effects, with the frontal cortex more prone to desensitisation 
than the striatum and hippocampus.  
Previous studies have demonstrated adolescent CDPPB treatment results in behavioural changes at adulthood. 
Clifton et al, reported chronic adolescent CDPPB treatment (PN 35- 47; 10 mg/kg/day) was able to prevent 
neonatal PCP-induced social novel discrimination deficits at adulthood (13 weeks old) [24]. These results suggest 
chronic adolescent CDPPB treatment can cause long-term neurochemical changes, particularly to the NMDA 
receptor, whereby pharmacological blockade induces social cognitive deficits. However, we did not observe 
changes to ionotropic glutamatergic receptor expression in the adult frontal cortex or hippocampus following 
adolescent CDPPB treatment. Although, despite the fact mGluR5 levels were unchanged at adolescence, we 
observed a delayed increase of mGluR5 in the adult frontal cortex. It is unclear why mGluR5 displayed a delayed 
increase in protein expression, however increased cortical mGluR5 expression has been associated with several 
mood disorders, including depression and anxiety [32]. Furthermore, lentiviral overexpression of mGluR5 in the 
frontal cortex has shown to produce depressive-and anxiety-like behaviours [33]. Whilst it is not clear if the 
increased mGluR5 expression observed at adulthood following CDPPB treatment may be associated with 
depressive- or anxiety-like behaviour, future studies should examine other behavioural parameters following 
adolescent CDPPB treatment. However, it must be acknowledged that naïve animals were used in this present 
study; it is possible that the use of a neurodevelopmental model schizophrenia, which already exhibits disturbed 
neurotransmission, could influence the effects of CDPPB on brain glutamatergic signalling. For example, mGluR5 
activation was shown to exert an effect on the GABAergic and dopaminergic systems, which are important for 
cognitive function [34, 35]. A recently developed mGluR5 PAM, VU049551, was shown to have cognitive 
enhancing effects independent of NMDA receptor activity; VU049551 demonstrated synaptic plasticity effects 
via the M1 muscarinic acetylcholine receptor [36], highlighting the role mGluR5 PAMs could play on other 
neurotransmitter systems, beyond glutamatergic receptors.  
The present study shows that chronic adolescent CDPPB treatment upregulates the expression of several 
glutamatergic receptors in the hippocampus. These changes were not present at adulthood, suggesting adolescent 
CDPPB treatment may not translate into long-term changes in glutamatergic signalling, at least using the treatment 
paradigm. Furthermore, we speculate a lower dose may increase CDPPB’s capacity to modulate NMDA and 
AMPA receptor activity, particularly in the frontal cortex. Whilst behavioural studies suggest adolescent CDPPB 
treatment can have effects at adulthood, these effects may be mediated via other neurotransmitter systems, such 
as the muscarinic and/or GABAergic system.  Further understanding the mechanisms underlying the effects of 
mGluR5 positive allosteric modulation can improve drug design and therapeutic strategy. 
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Fig. 1  a. Representative immunoblots of mGluR5 dimer, Norbin, Homer1b/c, NR1, NR2A, NR2B, GluA1, GluA2 
and PSD-95 in the adolescent hippocampus following adolescent CDPPB treatment. Representative GAPDH is 
shown for GluA1 blots only. Graphs illustrate the relative mean (+SEM) protein expression of b. dimeric mGluR5, 
c. Norbin, d. Homer1b/c, e. NR1, f. NR2A, g. NR2B, h. GluA1, i. GluA2 and j. PSD-95 in the adolescent 
hippocampus of vehicle (white bars) and CDPPB (black bars) treated rats (n=5-6/per treatment group).  *p<0.05 
vs. vehicle, **p<0.01 vs. vehicle 
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Fig. 2  a. Representative immunoblots of mGluR5 dimer, Norbin, Homer1b/c, NR1, NR2A, NR2B, GluA1, GluA2 
and PSD-95 in the adolescent frontal cortex following adolescent CDPPB treatment. Representative GAPDH is 
shown for GluA1 blots only. Graphs illustrate the relative mean (+SEM) protein expression of b. dimeric mGluR5, 
c. Norbin, d. Homer1b/c, e. NR1, f. NR2A, g. NR2B, h. GluA1, i. GluA2 and j. PSD-95 in the adolescent frontal 
cortex of vehicle (white bars) and CDPPB (black bars) treated rats (n=5-6/per treatment group)  
Fig. 3 a. Representative immunoblots of mGluR5 dimer, Norbin, Homer1b/c, NR1, NR2A, NR2B, GluA1, GluA2 
and PSD-95 in the adult hippocampus following adolescent CDPPB treatment. Representative GAPDH is shown 
for GluA1 blots only. Graphs illustrate the relative mean (+SEM) protein expression of b. dimeric mGluR5, c. 
Norbin, d. Homer1b/c, e. NR1, f. NR2A, g. NR2B, h. GluA1, i. GluA2 and j. PSD-95 in the adult hippocampus 
of vehicle (white bars) and CDPPB (black bars) treated rats (n=5-7/per treatment group).  *p<0.05 vs. vehicle 
Fig. 4 a. Representative immunoblots of mGluR5 dimer, Norbin, Homer1b/c, NR1, NR2A, NR2B, GluA1, GluA2 
and PSD-95 in the adult frontal cortex following adolescent CDPPB treatment. Representative GAPDH is shown 
for GluA1 blots only. Graphs illustrate the relative mean (+SEM) protein expression of b. dimeric mGluR5, c. 
Norbin, d. Homer1b/c, e. NR1, f. NR2A, g. NR2B, h. GluA1, i. GluA2 and j. PSD-95 in the adult frontal cortex 
of vehicle (white bars) and CDPPB (black bars) treated rats (n=5-7/per treatment group).  ***p<0.001 vs. vehicle 




